Distribution of C→T and T→C polymorphisms of the urokinase-type plasminogen activator gene in children with type 1 diabetes mellitus and insulin resistance

Clinical and Experimental Medicine

Volumn 4, Issue 4, 2005, Pages 202-206

  Majsterek, I ^a   Przybylowska, K ^a   Mlynarski, W ^b   Drzewoski, J ^b   Blasiak, J ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Genetic polymorphism; Insulin resistance; Type 1 diabetes mellitus; uPA gene

Indexed keywords

UROKINASE RECEPTOR; UROKINASE;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTRON; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; GENETICS; PRESCHOOL CHILD;

CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INSULIN RESISTANCE; MALE; POLYMORPHISM, GENETIC; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 17644375481     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-004-0057-9     Document Type: Article

References (33)

1. Hadjadj S, Guilloteau G, Weekers L, Bouhanick B, Fressinaud P, Marre M (2000) Differences in glycemic balance (but not weight) correlate positively with changes in absolute cardiovascular risk in diabetic patients. Arch Mal Coeur Vaiss 93:1033-1036
2. Miura J, Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y (2003) Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications 17:16-21
3. Bouhanick B, Raguin H, Rohmer V, Ebran JM, Simard G, Limal JM (2003) Description of microangiopathy in children with type 1 diabetes mellitus: a 19-year retrospective study. Diabetes Metab 29:395-402
4. Bouhanick B, Bellanne-Chantelot C, Salle A, Guilloteau G, Ebran JM (2002) Proliferative retinopathy in patients with type 1 diabetes of less than 5 years' duration. Diabetes Metab 28:141-144
5. Ustundag B, Canatan H, Cinkilinc N, Halifeoglu I, Bahcecioglu IH (2000) Angiotensin converting enzyme (ACE) activity levels in insulin-independent diabetes mellitus and effect of ACE levels on diabetic patients with nephropathy. Cell Biochem Funct 18:23-28
6. Duvnjak L, Vučković S, Car N, Metelko Ž (2001) Relationship between autonomic function, 24-h blood pressure, and albuminuria in normotensive, normoalbuminuric patients with Type 1 diabetes. J Diabetes Complications 15:314-319
7. Yang B, Cross DF, Ollerenshaw M, Millward BA, Demaine AG (2003) Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications 17:1-6
8. Haffner SM (1998) The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 19:583-592
9. Bouhanick B, Laboureau-Soares Barbosa S, Marre M (2000) Hypertension and diabetes. Arch Mal Coeur Vaiss 11:1429-1434
10. Marre M, Bouhanick B, Hadjadj S, Weekers L (1999) Contribution of arterial hypertension to vascular risk in diabetic patients. Diabetes Metab 3:27-31
11. Dollery CM, McEwan JR, Henney AM (1995) Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863-868
12. Johansson A, Boman K, Cederquist K, Forsberg H, Olsson T (2001) Increased levels of tPA antigen and tPA/PAI-1 complex in myotonic dystrophy. J Intern Med 49:503-510
13. Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, Takashi H, Yoshiyuki O, Shigeru K (2004) Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor. J Lab Clin Med 144:69-77
14. Mayer M (1990) Biochemical and biological aspects of the plasminogen activation system. Clin Biochem 23:197-211
15. Schmitt M, Hartbeck N, Thomassen C, Wihlem O, Reuning U, Ulm K, Hofler H, Janicke F, Graeff H (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78:285-296
16. Estricher A, Muhlhauser J, Carpentier JL, Orci L, Vassali JD (1990) The receptor for urokinase type plasminogen activator polaries expression of the protease to the leading edge of migrating monocytes and promotes deregulation enzyme inhibitor complex. J Cell Biol 111:783-792
17. Conese M, Blasi F (1995) Urokinase/urokinase receptor system, internalization/degradation of urokinase serpin complex: mechanism and regulation. Biol Chem Hoppe Seyler 376:143-155
18. Blasi F, Vassali JD, Dano K (1987) Urokinase-type activator. Proenzyme, receptor and inhibitors. J Cell Biol 104:801-804
19. Janicke F, Schmitt M, Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and their inhibitor PAI-1 in breast cancer. Semin Thromb Hemost 17:303-312
20. Knop A, Andewrsen PA, Andersen JA (1998) Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77:932-940
21. Sier CFM, Verspaget HW, Griffionen G, Verheijen JH, Quax PHA, Dooijeewaard G, De Briun PAF, Lambers CB (1991) Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasma. Implications of urokinase in colorectal carcinogenesis. Gastroenterology 101:1522-1528
22. Przybylowska K, Blasiak J, Kulig A, Romanowicz-Makowska H, Dziki A, Pander B (2000) A C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancer. J Exp Clin Cancer Res 20:569-572
23. Conne B, Berczy M, Belin D (1997) Detection of polymorphisms in the human urokinase-type plasminogen activator gene. Thromb Haemost 77:434-435
24. Grondahl-Hansen J, Christensen IJ, Rosenquist CH, Brunner N, Henning T, Dano K, Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521
25. Yoshimoto M, Ushiyama Y, Sakai M, Tamaki S, Hara H, Takahashi K, Sawasaki Y, Hanada K (1996) Characterization of single chain urokinase-type plasminogen activator with novel substitution amino-acid substitution in the kringle structure. Biochim Biophys Acta 1293:83-89
26. Almer LO, Pendolfi JM, Nilson JM (1975) Diabetic retinopathy and the fibrinolytic system. Diabetes 24:529-553
27. Tuttle HA, Davis-Gorman G, Goldman S, Copeland JG, McDonagh PF (2003) Platelet-neutrophil conjugate formation is increased in diabetic women with cardiovascular disease. Cardiovasc Diabetol 2:12
28. Bouhanick B, Hadjadj S, Marre M (1999) Microalbuminuria, glomerular filtration rate, and dietary fat and protein intakes in type 1 diabetes. Am J Clin Nutr 69:153
29. Durruty P, Carpentier C, Krause P, Garcia de los Rios M (2000) Evaluation of retinal involvement in type 2 diabetics with microalbuminuria. Rev Med Chil 128:1085-1292
30. Marre M, Hadjadj S, Bouhanick B (2000) Hereditary factors in the development of diabetic renal disease. Diabetes Metab 26:30-36
31. Aminot-Gilchrist DV, Anderson HD (2004) Insulin resistance-associated cardiovascular disease: potential benefits of conjugated linoleic acid. Am J Clin Nutr 79[Suppl 6]:1159S-1163S
32. Borgfeld C, Casselen B, Liu C-L, Hansson S, Lecander I, Astedt B (1998) High tissue content of urokinase plasminogen activator (uPA) is associated with higher stromal expression of uPA RNA in poorly differentiated serous ovarian carcinoma. Int J Cancer 79:588-595
33. Przybylowska K, Smolarczyk K, Kulig A, Romanowicz-Makowska H, Dziki A, Ulanska J, Pander B, Blasiak J (2002) Antigen levels of the urokinase-type plasminogen activator and gene polymorphisms in colorectal cancer. Cancer Lett 181:23-30